This is a knockout-validated antibody summary, based on the publication "EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).
Antibody: p-EPHA2 (Y588)
Catalog number: 12677
Summary: Rabbit monoclonal antibody raised against a synthetic phosphopeptide corresponding to residues surrounding Tyr588 of human EphA2 protein. Recognizes endogenous levels of EphA2 protein only when phosphorylated at Tyr588. This antibody may cross-react with other overexpressed phosphotyrosine proteins. It detects human protein and is predicted to react to mouse, rat, and monkey, based on 100% sequence homology. It has been used in western blotting and immunoprecipitation.
Validation Method: Western blot, WB
Antibody: p-EPHA2 (S897)
Catalog number: CY1108
Validation Method: Western blot, WB
Antibody: EPHA2, N-terminal
Catalog number: A302-024A
Validation Method: Western blot, WB
Antibody: EPHA2 C-terminal
Catalog number: sc-924
Validation Method: Western blot, WB
Antibody: EPHA2
Catalog number: 347400
Validation Method: immunohistochemistry, IHC
Tumor lysates from freshly isolated lung tumors from EGFRL858R+T790MEphA2+/+ or EGFRL858R+T790MEphA2-/- mice.
Supplemental Figure 4 for western blots [1].
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from any supplier or developed by the author(s), please notify us through feedback.